Funded in part by Novo Nordisk, Novo Nordisk Fonden
High-dose cholecalciferol supplementation to obese infertile men is sufficient to reach adequate vitamin D status
Holt R, Jorsal MJ, Yahyavi SK, Qin S, Juul A, Jørgensen N, Blomberg Jensen M
The British journal of nutrition · 7 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Company
- Novo Nordisk
- University or hospital
- Rigshospitalet
- Company
- Novo Nordisk Fonden
- Grants
- Novo Nordisk Fonden (NNF22OC0074704); Novo Nordisk Fonden (NNF17OC0026096)
Based on 3 listed funder(s).
Publication
- Published
- 2023-10-09 · Br J Nutr · vol. 131 · issue 4 · pp. 642–647
- Publisher
- Cambridge University Press
- Cited
- 10 citations · more than 84% of similar papers · 1.7× the field average
- References
- 29 works
- Access
- Free to read
- Research areas
- Vitamin D Research Studies · Hormonal and reproductive studies · Pharmacology and Obesity Treatment
- Keywords
- Vitamin D and neurology, Medicine, Cholecalciferol, Overweight, Placebo, Internal medicine, Obesity, Vitamin, Endocrinology, vitamin D deficiency
- MeSH
- humans, vitamin d deficiency, obesity, cholecalciferol, vitamins, vitamin d, double-blind method, dietary supplements, male, overweight
7 authors
From DK
- Rune HoltCopenhagen University Hospital; Gentofte Hospital; Rigshospitalet
- Mads Joon JorsalCopenhagen University Hospital; Gentofte Hospital; Rigshospitalet
- Sam Kafai YahyaviCopenhagen University Hospital; Gentofte Hospital; Rigshospitalet
- Simeng QinCopenhagen University Hospital; Gentofte Hospital; Rigshospitalet
- Anders JuulUniversity of Copenhagen; Copenhagen University Hospital; Rigshospitalet
- Niels JørgensenCopenhagen University Hospital; Rigshospitalet
Abstract
Obesity is associated with low vitamin D status, and the optimal supplement and dosage of cholecalciferol (vitamin D3) or calcidiol (25OHD) for individuals with obesity have been debated. We aimed to determine the effect of high-dose vitamin D3 supplementation on achieving adequate vitamin D levels among infertile men with normal weight v. obesity. Here, we present secondary end points from a single-centre, double-blinded, randomised clinical trial, comprising 307 infertile men randomised to active or placebo treatment for 150 days. Men in the active group initially received an oral bolus of 300 000 mg of vitamin D3, followed by daily supplementation with 1400 mg of vitamin D3 and 500 mg of calcium. Baseline BMI was listed as a predefined subgroup. At baseline, serum 25OHD was significantly higher in men with normal weight (BMI 2) compared with men with overweight (BMI 25-30 kg/m2) and obesity (BMI > 30 kg/m2) (48 nmol/l v. 45 nmol/l and 39 nmol/l, respectively; P = 0·024). After the intervention, men with normal weight, overweight and obesity treated with vitamin D3 had a significantly higher serum 25OHD compared with corresponding placebo-treated men (BMI 2: 92 nmol/l v. 53 nmol/l, BMI = 25-30 kg/m2: 87 nmol/l v. 49 nmol/l and BMI > 30 kg/m2: 85 nmol/l v. 48 nmol/l; P 3 supplementation to infertile men with obesity and low vitamin D status is sufficient to achieve adequate serum 25OHD levels.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.